You are currently viewing the EU version of the website.

View US version

en

Morphic

Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes

There are multiple pharmacotherapy options for type 2 diabetes mellitus (T2DM) including injectable glucagon-like peptide 1 receptor agonists (GLP-1RA). EndoBarrier is an innovative impermeable liner implanted endoscopically into the proximal intestine for up to one year, before removal. We compare the cost-effectiveness of three strategies in patients with suboptimally controlled type 2 diabetes despite at least 6 months’ liraglutide: EndoBarrier combined with  liraglutide; EndoBarrier without liraglutide; and liraglutide without EndoBarrier for  the treatment of obese patients with T2DM from a National Healthcare perspective.

ADA2018-abstract-Cost-effectiveness-analysis-submitted-8jan2018.pdf

Privacy Overview
Morphic Medical EU

We respect your privacy. Morphic Medical’s website may collect standard information such as IP address, browser type, and usage statistics to improve your experience. We do not collect sensitive personal data unless you choose to provide it (e.g. via contact forms).

By continuing to use this site, you acknowledge that:

  • We process your data in accordance with the:
    • EU General Data Protection Regulation (GDPR)
    • HIPPA (Health Insurance Portability and Accountability Act)
  • Any data collected is used only for site functionality, security, or user experience improvements
  • You have the right to access, correct, or delete your data at any time

To learn more, view our [Privacy Policy].

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Analytics

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Powered by  GDPR Cookie Compliance